Patent profile for the approved and in clinical trials Mpox vaccines.

Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox.

Nanoparticles applied to antineoplastic agents: a patent landscape.

Recently, research in the field of cancer nanotechnology has made notable progress, and, with the fast development of nanomaterials, new treatment strategies using nanoparticles are being explored that have the potential to overcome existing problems. The present review focuses on patenting as a key indicator of trends in nanoparticles with applications in the treatment of cancer. The impact of cancer on health and the use of nanoparticles are briefly described.

Pipeline of Known Chemical Classes of Antibiotics.

Many approaches are used to discover new antibiotic compounds, one of the most widespread being the chemical modification of known antibiotics. This type of discovery has been so important in the development of new antibiotics that most antibiotics used today belong to the same chemical classes as antibiotics discovered in the 1950s and 1960s. Even though the discovery of new classes of antibiotics is urgently needed, the chemical modification of antibiotics in known classes is still widely used to discover new antibiotics, resulting in a great number of compounds in the discovery and clinical pipeline that belong to existing classes.